[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nad":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618167","efficacy-and-safety-of-coenzyme-i-for-injection-on-vascular-aging-100618167",false,"NCT07328100","Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）","Inclusion Criteria:\n\n1. Ages 40-70 years;\n2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;\n3. Systolic Blood Pressure \\\u003C 160 mmHg and ≥ 140 mmHg or Diastolic BP \\\u003C 100 mmHg ≥ 90mmHg;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；\n2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；\n3. Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg；\n4. Diagnosis of malignant tumor；\n5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；\n6. History of severe allergies or infusion reactions；\n7. Women who are pregnant, breastfeeding, or planning pregnancy；\n8. Severe hepatic or renal dysfunction: ALT or AST \\> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m²；\n9. Concurrent participation in another clinical trial without completion of the follow-up period；\n10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.","ALL","40 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.",[27,28],"Vascular Aging","NAD","NOT_YET_RECRUITING","2025-12-28",{"date":32,"type":33},"2026-01-08","ACTUAL",{"date":35,"type":21},"2026-01-16",{"date":37,"type":21},"2027-12-31",{"name":39,"class":40},"Shanghai 10th People's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100608559","evaluation-of-the-impact-of-an-alteration-of-nad-metabolism-on-the-renal-prognosis-of-patients-admitted-to-intensive-care-ni-aki-100608559","NCT07203131","Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)","Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care","NI-AKI","Inclusion Criteria:\n\n* Patient, male or female aged over 18,\n* Patient admitted to intensive care for a reason with a high risk of ARI: shock, sepsis, cardio-circulatory arrest, post-operative unscheduled surgery, post-operative cardiac surgery,\n* Patient with normal renal function on admission,\n* Patient affiliated to or beneficiary of a social security scheme,\n* Patient having been informed and having given his\u002Fher free, informed and written consent\n\nExclusion Criteria:\n\n* Minor patient,\n* History of chronic kidney disease,\n* History of kidney transplant,\n* Admission for a reason with a low risk of ARI (neuroresuscitation, voluntary drug intoxication with anxiolytics - antidepressants - psychotropic drugs),\n* Acute non-infectious respiratory failure, (scheduled surgery other than cardiac surgery)\n* Patient hospitalized without consent,\n* Patient in a period of exclusion due to another research still in progress at the time of inclusion,\n* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision,\n* Pregnant, breastfeeding or parturient woman.","18 Years",{"count":52,"type":21},150,[24],"Among all patients admitted to intensive care, it is estimated that more than half of them are exposed during their stay to acute renal failure (ARF). Impacting the vital prognosis to short term, the occurrence of renal failure is not without consequences in intensive care survivors, presenting an increased risk of death mainly mediated by an excess risk with regard to chronic kidney disease and\u002For certain cardiovascular pathologies.\n\nMalnutrition, particularly vitamin deficiency, has already been reported as a risk factor for AKI. Studies on two models (animal and human) have recently highlighted the importance of NAD+ production failure in the onset of renal failure.\n\nNAD+ synthesis can be done from tryptophan or via a salvage pathway from vitamin PP.\n\nIn a phase 2 study in patients undergoing cardiac surgery, vitamin B3 supplementation was accompanied by a reduction in the occurrence of AKI and a limitation of the duration \u002F intensity of renal dysfunction.\n\nThis innovative research aims to identify an alteration in the metabolic pathway of NAD+ production as a risk factor for AKI in intensive care patients. This would be the first study to address this issue in this specific population.\n\nThe main objective of this research is to describe the association between the urinary Quinolinate\u002FTryptophan ratio on admission and the occurrence of acute renal failure in patients admitted to intensive care unit.",[56,28],"Acute Renal Insufficiency","RECRUITING","2025-09-29",{"date":60,"type":33},"2025-10-02",{"date":62,"type":33},"2025-03-17",{"date":64,"type":21},"2025-12-05",{"name":66,"class":40},"Ramsay Générale de Santé",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":41},"100603152","comparison-of-two-qualia-nad-formulations-on-intracellular-nad-levels-100603152","NCT07132801","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial","Inclusion Criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nHealthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks\u002Fshots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study\n\nExclusion Criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent",true,"35 Years","75 Years",{"count":78,"type":21},180,[24],"This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[28,82],"NAD+ Levels in the Blood",[84,28],"NAD Supplementation","2025-08-13",{"date":87,"type":33},"2025-08-20",{"date":89,"type":21},"2025-10-13",{"date":91,"type":21},"2025-12-15",{"name":93,"class":94},"Qualia Life Sciences","INDUSTRY"]